Sun Pharma adds generic tamsulosin and rivastigmine to portfolio

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Sun Pharma adds generic tamsulosin and rivastigmine to portfolio

Generics/News | Posted 13/08/2010 0 Post your comment

Sun Pharma is gathering speed with a barrage of generic versions recently coming onto the market and with an extensive pipeline on the way. The latest generics to come out of the company include versions of tamsulosin and rivastigmine.

The Indian-based company recently announced that they had received approval from the US FDA for their generic version of Boehringer Ingelheim Pharmaceuticals treatment for enlarged prostates, Flomax (tamsulosin hydrochloride).

Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia.

The company also announced the launch of a generic version of Novartis’s dementia treatment Exelon after its abbreviated new drug application (ANDA) was approved by the FDA.

The generic rivastigmine capsules come in four strengths: 1.5 mg, 3 mg, 4.5 mg and 6 mg. These strengths of Exelon have annual sales of approximately US$130 million in the US.

Sun Pharma, being one of the first to file an ANDA for generic Exelon with a paragraph IV certification, shares a 180-day marketing exclusivity.

Rivastigmine tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer's type or associated with Parkinson’s disease.

Sun Pharma, which started out with just five products is now one of the leading pharma companies in India, and is increasing its presence as a global generics manufacturer.

References:

Sun Pharma Press Release. Sun Pharma announces launch of generic Exelon in US. 1 July 2010

Sun Pharma Press Release. Sun Pharma announces US FDA approval for generic Flomax. 16 July 2010